MariMed Reports Improved Q1 Profitability with 44% Adjusted EBITDA Growth

summarizeSummary

MariMed Inc. announced its first-quarter 2026 financial results, showing improved profitability with a 44% increase in Adjusted EBITDA and a narrower net loss compared to the prior year.

check_boxKey Events

• Adjusted EBITDA Surges

  Non-GAAP Adjusted EBITDA increased by 44% year-over-year to $3.6 million in Q1 2026, up from $2.5 million in Q1 2025, with the Adjusted EBITDA margin expanding to 9% from 7%.

• Net Loss Narrows

  The GAAP net loss improved to $(3.8) million in Q1 2026, compared to a net loss of $(5.5) million in the same period last year.

• Revenue Growth

  Revenue for the first quarter of 2026 grew modestly by 4.2% to $39.5 million, up from $37.9 million in Q1 2025.

• Debt Restructuring Highlighted

  The company highlighted its March 2, 2026, restructuring of $14.725 million in Series B Convertible Preferred Stock obligations, which extended the weighted average maturity to 4.6 years and enhanced liquidity.

auto_awesomeAnalysis

MariMed Inc. reported a significant 44% year-over-year increase in Adjusted EBITDA and a reduced net loss for Q1 2026. This operational improvement is crucial for the micro-cap company, especially following its recent debt restructuring and ongoing efforts to strengthen its financial position in a challenging industry.